Weimer 2002.

Methods	Study type: parallel RCT Study time frame/year of transplantation: 1998 to 2000 Duration of follow‐up: 2 years
Participants	Country: Germany Setting: single centre Patients receiving a kidney allograft (deceased or living donor) Deceased donor: 75% Previous transplantation: 14.3% PRA level: max 8% HLA mismatch (mean): 2.6 Cold ischaemia time (mean): 13 h Delayed graft function: 16 % Number: treatment group (31); control group (25) Mean age: 47 years Sex: 39% male Exclusion criteria: not reported
Interventions	Treatment group MMF Dose unclear Control group AZA Dose unclear Concomitant immunosuppression Induction antibody: ATG if previous transplantation, or PRA > 5 %, or delayed graft function CsA‐ME, target C0 (month 3): not reported Corticosteroids
Outcomes	Death Graft loss Primary non‐function Acute rejection CAN Infections Kidney function measures (SCr, CrCl)
Notes	Additional intervention arm (Tac/AZA) Publication: full journal article Language: English
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information about the sequence generation process to permit judgment
Allocation concealment (selection bias)	Unclear risk	Randomisation stated, but no information on allocation method used is available
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgment
Incomplete outcome data (attrition bias) All outcomes	Low risk	ITT analysis reported; all patients followed up or accounted for
Selective reporting (reporting bias)	Low risk	The published report included most expected outcomes regarding efficacy and safety
Other bias	High risk	The study was supported in part by the Fujisawa, Roche, Novartis, Biotest and Fresenius companies